---
title: "Claseprubart (DNTH103) in Generalized myasthenia gravis: Pharmacodynamics"
description: "Formulary evidence on Claseprubart (DNTH103) in Generalized myasthenia gravis: Pharmacodynamics. Topics: Classical pathway inhibition in healthy volunteers: phase 1; In vitro affinity and potency compared with riliprubart; Neurotransmission and muscle contraction in an in vitro myasthenia gravis model; Upstream versus downstream complement blockade: C3a, C3b, and membrane attack complex; 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-15T22:20:57-05:00"
---

# Claseprubart (DNTH103) in Generalized myasthenia gravis: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Classical pathway inhibition in healthy volunteers: phase 1

> “DNTH103 showed dose-dependent inhibition of the classical pathway measured by CH50 inhibition and Wieslab® assay”
> “Phase 1 data confirm • ~60-day half-life • IC90 calculated at 87μg/mL • Dosing modeled • 15mg/kg IV on Day 0 • 300mg SC Q2W starting Day 7”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

<a id="topic-2.1.2.6.2-2"></a>

### In vitro affinity and potency compared with riliprubart

| Assay | Claseprubart (DNTH103) | Riliprubart |
| --- | --- | --- |
| Binding affinity to human active C1s, KD (KinExa) | “9pM” | “75pM” |
| Binding affinity to human active C1s, KD (SPR) | “8pM” | “35pM” |
| C4 cleavage by human active C1s, IC90 (nM) | “0.47” | “3.69” |
| Wieslab classical pathway assay in human serum, IC90 (μg/mL) | “0.45” | “5.4” |
| CH50 assay of RBC lysis in human serum, IC90 (μg/mL) | “98” | “668” |
| Liposome lysis in human serum, IC90 (μg/mL) | “14.7” | “39.8” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.2-3"></a>

### Neurotransmission and muscle contraction in an in vitro myasthenia gravis model

> “Serum from MG patients used in a validated commercially available humanized in-vitro MG model1,2,3 simulating a relevant clinical phenotype of impaired neurotransmission and muscle contraction • 7 MG patient sera samples were collected; 3 were AChR+ and used in the study • Evaluated response to anti-C5 antibody§ and DNTH103 via fatigue index (measures neurotransmission and muscle contraction)”
> “A reduction in fatigue index indicates improvement in neurotransmission and muscle contraction”
> “DNTH103 is a highly potent picomolar inhibitor of active C1s that is as effective in neurotransmission and muscle contraction as an anti-C5 antibody in a preclinical model of Myasthenia Gravis”

Source: [Gokhale et al. (2024)](https://investor.dianthustx.com/static-files/385658f0-0e93-4df3-8b31-a1c0077c9024)

| Treatment with AChR+ MG patient sera | Change in muscle contraction fatigue index from baseline |
| --- | --- |
| Ravulizumab* (1 μM), n=3 | “-14.8%” |
| DNTH103 (0.1 μM), n=3 | “-24.8%” |
| DNTH103 (1 μM), n=3 | “-27.8%” |

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

<a id="topic-2.1.2.6.2-4"></a>

### Upstream versus downstream complement blockade: C3a, C3b, and membrane attack complex

> “To determine whether aC1s inhibition by claseprubart suppresses generation of C3a, C3b and membrane attack complex (MAC) in vitro, and whether its complement inhibition profi le is different to that of the C5 inhibitor ravulizumab.”
> “In head-to-head WIESLAB® Complement Classical Pathway assays, claseprubart produced comparable inhibition of MAC formation compared to ravulizumab, confirming similar levels of terminal pathway blockade (Figure 2).”
> “In contrast, only upstream aC1s inhibition with claseprubart resulted in near complete inhibition of the generation of C3a, while ravulizumab did not (Figure 3).”
> “Similarly, in the C3b assay, C3b-positive RBCs were all but undetectable in claseprubart-treated assay samples, but levels were unaffected in samples treated with ravulizumab (Figure 4).”

Source: [Shelly et al. (2026)](https://investor.dianthustx.com/static-files/1c8f7991-8993-4f05-8d16-194596a7c8c4)

<a id="topic-2.1.2.6.2-5"></a>

### Exposure and response in the MaGic open-label extension

> “PK of ~65 μg/mL at week 4 after only two 600mg/4mL doses is substantially lower than steady state seen with 300mg/2mL dosing of ~100-120 μg/mL • Robust reductions in MG-ADL and QMG are achieved by week 4, after just two 600mg/4mL doses and remain stable in subsequent weeks • Growing external evidence further supports that lower levels of complement inhibition (<90%) may be sufficient for efficacy in gMG”
> “PK levels approximately half of 300mg/2mL Q2W steady state resulted in robust reductions on MG-ADL & QMG”

Source: [Dianthus Therapeutics presentation (2026e)](https://investor.dianthustx.com/static-files/9868f92c-aaba-4dcb-87a6-6881536645d1)

> “A robust MG-ADL decline at week 4 in the open-label extension (OLE) of -2.5 points and QMG score reduction of -3.2 points for patients on placebo during the RCT who received only two doses of claseprubart 600mg/4mL Q2W without a loading dose and achieved a PK level far below the steady state of 300mg/2mL Q2W, supporting potential for Q4W dosing of 300mg/2mL”

Source: [Dianthus Therapeutics (2025c)](https://investor.dianthustx.com/news-releases/news-release-details/dianthus-therapeutics-highlights-new-claseprubart-data-presented)

## Related pages
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Generalized myasthenia gravis](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/executive-summary.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/clinical-evidence.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/economics.md)
- [Claseprubart (DNTH103) in Generalized myasthenia gravis: References](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--generalized-myasthenia-gravis/references.md)
